pH-Responsive Lipid Nanocapsules: A Promising Strategy for Improved Resistant Melanoma Cell Internalization

SIMPLE SUMMARY: Only 13 to 50% of patients with metastatic melanoma respond to new commercialized therapies. The reason why the same chemotherapeutic treatments yield different responses in patients can be attributed to the degree of multidrug resistance (MDR) developed by the host tumor cells. For...

Descripción completa

Detalles Bibliográficos
Autores principales: Pautu, Vincent, Lepeltier, Elise, Mellinger, Adélie, Riou, Jérémie, Debuigne, Antoine, Jérôme, Christine, Clere, Nicolas, Passirani, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122844/
https://www.ncbi.nlm.nih.gov/pubmed/33922267
http://dx.doi.org/10.3390/cancers13092028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122844/
https://www.ncbi.nlm.nih.gov/pubmed/33922267
http://dx.doi.org/10.3390/cancers13092028

Ejemplares similares